Edwards Lifesciences Corp  

(Public, NYSE:EW)   Watch this stock  
Find more results for EW
+0.36 (0.34%)
Real-time:   2:27PM EST
NYSE real-time data - Disclaimer
Currency in USD
Range 106.07 - 107.74
52 week 81.12 - 121.45
Open 106.60
Vol / Avg. 471,992.00/1.64M
Mkt cap 22.74B
P/E 31.24
Div/yield     -
EPS 3.44
Shares 211.62M
Beta 0.46
Inst. own 85%
Jan 30, 2018
Q4 2017 Edwards Lifesciences Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 7, 2017
Edwards Lifesciences Corp Investor Conference - 8:00AM EST - Add to calendar
Oct 24, 2017
Q3 2017 Edwards Lifesciences Corp Earnings Call - Webcast
Oct 24, 2017
Q3 2017 Edwards Lifesciences Corp Earnings Release
Sep 7, 2017
Edwards Lifesciences Corp at Wells Fargo Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 20.71% 19.22%
Operating margin 25.78% 24.90%
EBITD margin - 29.86%
Return on average assets 12.84% 13.30%
Return on average equity 22.36% 22.24%
Employees 11,100 -
CDP Score - C


1 Edwards Way
IRVINE, CA 92614-5688
United States - Map
+1-949-2502500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Officers and directors

Michael A. Mussallem Chairman of the Board, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott B. Ullem Chief Financial Officer, Corporate Vice President
Age: 50
Bio & Compensation  - Reuters
Donald E. Bobo Jr. Corporate Vice President - Heart Valve Therapy
Age: 55
Bio & Compensation  - Reuters
Catherine M. Szyman Corporate Vice President- Critical Care
Age: 50
Bio & Compensation  - Reuters
Patrick Bruno Verguet Corporate Vice President- Europe, Middle East and Africa
Age: 59
Bio & Compensation  - Reuters
Huimin Wang M.D. Corporate Vice President- Japan, Asia and Pacific
Age: 60
Bio & Compensation  - Reuters
Larry L. Wood Corporate Vice President - Transcatheter Heart Valve Therapy
Age: 51
Bio & Compensation  - Reuters
Bernard J. Zovighian Corporate Vice President -Surgical Heart Valve Therapy
Age: 49
Bio & Compensation  - Reuters
Kieran T. Gallahue Independent Director
Age: 53
Bio & Compensation  - Reuters
Leslie Stone Heisz Independent Director
Age: 56
Bio & Compensation  - Reuters